Fig. 3
The first-line PD-1 group and PD-L1 group were used to treat patients with advanced non-small cell lung cancer after progression to receive a new immune treatment regimen.
Fig. 3 | Scientific Reports
The first-line PD-1 group and PD-L1 group were used to treat patients with advanced non-small cell lung cancer after progression to receive a new immune treatment regimen.
